Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience

European Journal of Cancer

Volumn 41, Issue 17, 2005, Pages 2655-2661

  Steger, G G ^a   Bartsch, R ^a   Wenzel, C ^a   Pluschnig, U ^a   Hussian, D ^a   Sevelda, U ^a   Locker, G J ^a   Gnant, M F ^a   Jakesz, R ^a   Zielinski, C C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced breast cancer; Clinical benefit; Fulvestrant; Hormone receptor positive; Pre treated

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; FEMALE; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTRADIOL; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 27744527544     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.07.016     Document Type: Article

References (21)

1. R.W. Carlson, B.O. Anderson, and W. Bensinger NCCN Practice Guidelines for Breast Cancer JNCCN 1 2003 148 188
2. A.U. Buzdar, and G. Hortobagyi Update on endocrine therapy for breast cancer Clin Cancer Res 4 1998 527 534
3. G.N. Hortobagyi Progress in endocrine therapy for breast carcinoma Cancer 83 1998 1 6
4. A.E. Wakeling, M. Dukes, and J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res 51 1991 3867 3873
5. A.E. Wakeling Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 2000 17 28
6. J.F.R. Robertson, R.I. Nicholson, and N.J. Bundred Comparison of the short-term biological effects of fulvestrant with (ICI 182, 780) tamoxifen in postmenopausal women with primary breast cancer Breast Cancer Res Treat 59 2000 99
7. A. Howell, J.F.R. Robertson, and J. Quaresma Albano Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
8. C.K. Osborne, J. Pippen, and S.E. Jones Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
9. J.F. Robertson, C.K. Osborne, and A. Howell Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229 238
10. J. Pippen, C.K. Osborne, and A. Howell Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials Breast Cancer Res Treat 82 Suppl. 1 2003 S101 (abstr 426)
11. A. Reines, B. Neumeister, and J. Spona Immunocytochemical localization of estrogen and progesterone receptors and prognosis in human primary breast cancer Cancer Res 50 1990 7057 7061
12. L. Perey, B. Thürlimann, and H. Hawle Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors Breast Cancer Res Treat 76 Suppl. 1 2002 S72 (abstr 249)
13. S. Franco, A. Perez, and E. Tan-Chiu Fulvestrant (Faslodex(R)) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience Breast Cancer Res Treat 82 Suppl. 1 2003 S105 (abstr 439)
14. L. Petruzelka, and M. Zimovjanova Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - results from an expanded access programme Eur J Cancer 2 Suppl. 2004 132 (abstr 264)
15. I. Vergote, J.F.R. Robertson, and U. Kleeberg Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy Breast Cancer Res Treat 79 2003 207 211
16. A. Howell Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies Breast Cancer Res Treat 76 Suppl. 1 2002 S72 (abstr 251)
17. J.F.R. Robertson, A. Howell, and P. Abram Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women Ann Oncol 13 Suppl. 5 2002 46 (abstr 164O)
18. A. Howell, J.F.R. Robertson, and P. Abram Comparison of fulvestrant v tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 2004 1605 1613
19. R.I. Nicholson, J.M.W. Gee, and J. Knowlden The biology of antihormone failure in breast cancer Breast Cancer Res Treat 80 2003 29 34
20. R.J. Pietras, D.C. Marquez, and H.W. Chen Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene Breast Cancer Res Treat 82 Suppl. 1 2003 S12 (abstr 22)
21. R.W. Carlson, and I.C. Henderson Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole Breast Cancer Res Treat 80 2003 19 26